Discontinued — last reported Q4 '25
Nvidia Acquisitions decreased by 76.2% to $165.00M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 69.6%, from $542.00M to $165.00M. Over 4 years (FY 2022 to FY 2026), Acquisitions shows an upward trend with a 55.4% CAGR.
High spending indicates an aggressive growth strategy, while low spending may indicate a focus on organic growth or debt reduction.
This represents the net cash outflow for the purchase of other businesses or strategic assets, adjusted for any cash acq...
Highly variable; pharmaceutical companies frequently use M&A to offset patent cliffs and expand therapeutic portfolios.
acquisitions| Q1 '21 | Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $0.00 | $203.00M | $60.00M | $36.00M | $13.00M | $0.00 | $0.00 | $83.00M | $0.00 | $0.00 | $0.00 | $39.00M | $278.00M | $148.00M | $542.00M | $383.00M | $294.00M | $693.00M | $165.00M |
| QoQ Change | — | — | — | -70.4% | -40.0% | -63.9% | -100.0% | — | — | -100.0% | — | — | — | +612.8% | -46.8% | +266.2% | -29.3% | -23.2% | +135.7% | -76.2% |
| YoY Change | — | — | — | — | — | — | -100.0% | -100.0% | +130.6% | -100.0% | — | — | -53.0% | — | — | — | +882.1% | +5.8% | +368.2% | -69.6% |